InhibitorSelect Wnt Signaling Pathway Inhibitor Panel

Toxicity: Irritant (B)

A panel containing 15 potent and selective inhibitors useful for the study of the Wnt signaling pathway. This panel contains the following inhibitors: 1 mg of Casein Kinase I Inhibitor, D4476 (Cat. No. 218696); 5 mg Casein Kinase II Inhibitor III, TBCA (Cat. No. 218710); 10 mg of β-Catenin/Tcf Inhibitor, FH535 (Cat. No. 219330); 1 mg of GSK-3 Inhibitor IX (Cat. No. 361550); 1 mg of PKG Iα Inhibitor, Cell-Permeable (Cat. No. 370655); 1 mg of H-89, Dihydrochloride (Cat. No. 371963); 100 µg of K-252a, Nocardiopsis sp. (Cat. No. 420298); 5 mg of JNK Inhibitor II (Cat. No. 420119); 1 mg of KN-93 (Cat. No. 422708); 5 mg of LY 294002 (Cat. No. 440202); 1 mg of (5Z)-7-Oxozeaenol, Curvularia (Cat. No. 499610); 1 mg of PP2 (Cat. No. 529573); 100 µg of Rapamycin (Cat. No. 553210); 1 mg of SB 202190 (Cat. No. 559388); 1 mg of U0126 (Cat. No. 662005). Also provided with 15 ml of anhydrous DMSO (Cat. No. KP31817). Supplied with a data sheet.

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C) each inhibitor. Each inhibitor solution is stable for up to 3 months at -20°C.

Please refer to information provided on the CD for reconstitution information of individual inhibitors.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany